Skip to main content
Midas Edge

Fortress Biotech Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

FBIO$1.99+7.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity

For the Year Ended December 31, 2023

​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Common · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Series A Preferred Stock · ​ · Common Stock · ​ · Shares · ​ · Paid-In · ​ · Accumulated · ​ · Non-Controlling · ​ · Stockholders'
($ in thousands except for share amounts) · Shares · ​ · Shares · Amount · Issuable · Capital · Deficit · Interests · Equity
Balance at December 31, 20223,427,138​$37,366,283​$7​$—`$675,944​$(634,233)​$8,304​$50,025
Stock-based compensation expense—​——​—​—​17,029​—​—​17,029
Issuance of common stock related to equity plans—​—224,690​—​—​—​—​—​—
Issuance of stock for public offerings, net​—​—6,994,526​7​—​22,078​—​—​22,085
Issuance of common stock for at-the-market offering, net—​—224,003​—​—​2,041​—​—​2,041
Warrant charge in conjunction with Oaktree debt​​​​​​​​​​​​​​​272​​​​​​​​272
Common shares issued for dividend on partner company's convertible preferred shares​—​—58,551​—​—​266​—​—​266
Payment of Series A perpetual preferred stock dividends—​——​—​—​(8,032)​—​—​(8,032)
Exercise of warrants for cash—​—225,000​1​—​382​—​—​383
Partner companies’ proceeds from stock and warrants, net—​—​​—​—​59,956​—​—​59,956
Partner companies' at-the-market offering, net—​——​—​—​4,620​—​—​4,620
Partner company’s exercise of options for cash—​——​—​—​121​—​—​121
Issuance of common stock under partner company’s ESPP—​——​—​—​178​—​—​178
Partner company’s dividends declared and paid—​——​—​—​(736)​—​—​(736)
Partner company’s redemption of preferred shares—​——​—​—​(400)​—​—​(400)
Issuance of partner company’s common shares for research and development expenses—​——​—​—​1,240​—​—​1,240
Deconsolidation/dissolution of partner companies—​——​—​—​—​—​6,693​6,693
Non-controlling interest in subsidiaries—​——​—​—​(57,563)​—​57,563​—
Net loss attributable to non-controlling interest—​——​—​—​—​—​(93,517)​(93,517)
Net loss attributable to common stockholders—​——​—​—​—​(60,637)​—​(60,637)
Balance at December 31, 2023​3,427,138​$315,093,053​$15​$—​$717,396​$(694,870)​$(20,957)​$1,587

Consolidated Statements of Changes in Stockholders’ Equity

For the Year Ended December 31, 2022

​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Common · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Series A Preferred Stock · ​ · Common Stock · ​ · Shares · ​ · Paid-In · ​ · Accumulated · ​ · Non-Controlling · ​ · Stockholders'
($ in thousands except for share amounts) · Shares · ​ · Shares · Amount · Issuable · Capital · Deficit · Interests · Equity
Balance at December 31, 20213,427,138​$36,762,368​$7​$—​$656,127​$(547,463)​$117,203​$225,877
Stock-based compensation expense—​——​—​—​​22,987​—​—​22,987
Issuance of common stock related to equity plans—​—327,586​—​—​​174​—​—​174
Issuance of common stock for at-the-market offering, net—​​—​276,329​​—​​—​​6,053​​—​​—​6,053
Payment of Series A perpetual preferred stock dividends—​——​—​—​​(8,031)​—​—​(8,031)
Partner company’s offering, net—​——​—​—​​3,205​—​—​3,205
Partner companies' at-the-market offering, net—​——​—​—​​16,370​—​—​16,370
Issuance of common stock under partner company’s ESPP—​——​—​—​​206​—​​—​206
Partner company’s dividends declared and paid—​——​—​—​​(749)​—​—​(749)
Partner company’s exercise of options for cash—​——​—​—​​142​—​—​142
Partner company’s exercise of warrants for cash—​——​—​—​​148​—​—​148
Partner company’s reclassification of warrant liability to equity—​——​—​—​​89​—​—​89
Partner company’s repurchase of stock—​——​—​—​​(1,105)​—​—​(1,105)
Partner company’s stock adjustment—​——​—​—​​(29)​—​—​(29)
Partner company’s net settlement of shares withheld for taxes​​​​​​​​​​​​​​​(1,698)​​​​​​​​(1,698)
Partner company’s warrants issued in conjunction with debt​—​​—​—​​—​​—​​384​​—​​—​​384
Partner company’s retained earnings adjustment​—​​—​—​​—​​—​​195​​(195)​​—​​—
Partner company’s redemption of preferred shares​—​​—​—​​—​​—​​(85)​​—​​—​​(85)
Non-controlling interest in subsidiaries—​​—​—​​—​​—​​(18,439)​​—​​18,439​—
Net loss attributable to non-controlling interest—​​—​—​​—​​—​​—​​—​​(127,338)​(127,338)
Net loss attributable to common stockholders—​​—​—​​—​​—​​—​​(86,575)​​—​(86,575)
Balance at December 31, 20223,427,138​$37,366,283​$7​$—`$675,944​$(634,233)​$8,304​$50,025
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.